Matthew L MacDonald1, Ying Ding2, Jason Newman1, Scott Hemby3, Peter Penzes4, David A Lewis1, Nathan A Yates5, Robert A Sweet6. 1. Departments of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania. 2. Department of Biostatistics, University of Pittsburgh, Pittsburgh. 3. Neuroscience Program, Wake Forest University School of Medicine, Winston-Salem, North Carolina; Department of Physiology & Pharmacology, Wake Forest University School of Medicine, Winston-Salem, North Carolina. 4. Departments of Physiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois; Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois. 5. Biomedical Mass Spectrometry Center, University of Pittsburgh, Pittsburgh, Pennsylvania; Veterans Integrated Service Network 4 Mental Illness Research, Education and Clinical Center, Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, Pennsylvania. 6. Departments of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania; Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania; Veterans Integrated Service Network 4 Mental Illness Research, Education and Clinical Center, Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, Pennsylvania.. Electronic address: sweetra@upmc.edu.
Abstract
BACKGROUND: Impaired glutamatergic signaling is believed to underlie auditory cortex pyramidal neuron dendritic spine loss and auditory symptoms in schizophrenia. Many schizophrenia risk loci converge on the synaptic glutamate signaling network. We therefore hypothesized that alterations in glutamate signaling protein expression and co-expression network features are present in schizophrenia. METHODS: Gray matter homogenates were prepared from auditory cortex gray matter of 22 schizophrenia and 23 matched control subjects, a subset of whom had been previously assessed for dendritic spine density. One hundred fifty-five selected synaptic proteins were quantified by targeted mass spectrometry. Protein co-expression networks were constructed using weighted gene co-expression network analysis. RESULTS: Proteins with evidence for altered expression in schizophrenia were significantly enriched for glutamate signaling pathway proteins (GRIA4, GRIA3, ATP1A3, and GNAQ). Synaptic protein co-expression was significantly decreased in schizophrenia with the exception of a small group of postsynaptic density proteins, whose co-expression increased and inversely correlated with spine density in schizophrenia subjects. CONCLUSIONS: We observed alterations in the expression of glutamate signaling pathway proteins. Among these, the novel observation of reduced ATP1A3 expression is supported by strong genetic evidence indicating it may contribute to psychosis and cognitive impairment phenotypes. The observations of altered protein network topology further highlight the complexity of glutamate signaling network pathology in schizophrenia and provide a framework for evaluating future experiments to model the contribution of genetic risk to disease pathology. Published by Elsevier Inc.
BACKGROUND: Impaired glutamatergic signaling is believed to underlie auditory cortex pyramidal neuron dendritic spine loss and auditory symptoms in schizophrenia. Many schizophrenia risk loci converge on the synaptic glutamate signaling network. We therefore hypothesized that alterations in glutamate signaling protein expression and co-expression network features are present in schizophrenia. METHODS: Gray matter homogenates were prepared from auditory cortex gray matter of 22 schizophrenia and 23 matched control subjects, a subset of whom had been previously assessed for dendritic spine density. One hundred fifty-five selected synaptic proteins were quantified by targeted mass spectrometry. Protein co-expression networks were constructed using weighted gene co-expression network analysis. RESULTS: Proteins with evidence for altered expression in schizophrenia were significantly enriched for glutamate signaling pathway proteins (GRIA4, GRIA3, ATP1A3, and GNAQ). Synaptic protein co-expression was significantly decreased in schizophrenia with the exception of a small group of postsynaptic density proteins, whose co-expression increased and inversely correlated with spine density in schizophrenia subjects. CONCLUSIONS: We observed alterations in the expression of glutamate signaling pathway proteins. Among these, the novel observation of reduced ATP1A3 expression is supported by strong genetic evidence indicating it may contribute to psychosis and cognitive impairment phenotypes. The observations of altered protein network topology further highlight the complexity of glutamate signaling network pathology in schizophrenia and provide a framework for evaluating future experiments to model the contribution of genetic risk to disease pathology. Published by Elsevier Inc.
Authors: Jyrki Ahveninen; Iiro P Jääskeläinen; Daria Osipova; Matti O Huttunen; Risto J Ilmoniemi; Jaakko Kaprio; Jouko Lönnqvist; Marko Manninen; Satu Pakarinen; Sebastian Therman; Risto Näätänen; Tyrone D Cannon Journal: Biol Psychiatry Date: 2006-07-28 Impact factor: 13.382
Authors: Robert A Sweet; Joseph N Pierri; Sungyoung Auh; Allan R Sampson; David A Lewis Journal: Neuropsychopharmacology Date: 2002-12-03 Impact factor: 7.853
Authors: Handan Gunduz-Bruce; Robert M G Reinhart; Brian J Roach; Ralitza Gueorguieva; Stephen Oliver; Deepak C D'Souza; Judith M Ford; John H Krystal; Daniel H Mathalon Journal: Biol Psychiatry Date: 2011-10-29 Impact factor: 13.382
Authors: Diana E Moga; William G M Janssen; Prabhakar Vissavajjhala; Sharon M Czelusniak; Thomas M Moran; Patrick R Hof; John H Morrison Journal: J Comp Neurol Date: 2003-07-14 Impact factor: 3.215
Authors: Stephen M Lawrie; Christian Buechel; Heather C Whalley; Christopher D Frith; Karl J Friston; Eve C Johnstone Journal: Biol Psychiatry Date: 2002-06-15 Impact factor: 13.382
Authors: Matthew L MacDonald; Daley Favo; Megan Garver; Zhe Sun; Dominique Arion; Ying Ding; Nathan Yates; Robert A Sweet; David A Lewis Journal: Neuropsychopharmacology Date: 2018-11-02 Impact factor: 7.853
Authors: Robert A Sweet; Matthew L MacDonald; Caitlin M Kirkwood; Ying Ding; Tadhg Schempf; Jackie Jones-Laughner; Julia Kofler; Milos D Ikonomovic; Oscar L Lopez; Megan E Garver; Nicholas F Fitz; Radosveta Koldamova; Nathan A Yates Journal: Mol Cell Proteomics Date: 2016-04-21 Impact factor: 5.911
Authors: Y Iwata; S Nakajima; T Suzuki; R S E Keefe; E Plitman; J K Chung; F Caravaggio; M Mimura; A Graff-Guerrero; H Uchida Journal: Mol Psychiatry Date: 2015-06-16 Impact factor: 15.992
Authors: Matthew L MacDonald; Jamil Alhassan; Jason T Newman; Michelle Richard; Hong Gu; Ryan M Kelly; Alan R Sampson; Kenneth N Fish; Peter Penzes; Zachary P Wills; David A Lewis; Robert A Sweet Journal: Am J Psychiatry Date: 2017-03-31 Impact factor: 18.112